Oncology Growth Stabilizes Merck Q4: Management Projects $70B Long-Term Potential (MRK Q4 2025 Earnings Call)
Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.
Merck delivered mixed fourth-quarter results, balancing steady oncology portfolio expansion against persistent weakness in its vaccine business. The company posted $16.4 billion in quarterly revenue, overcoming a substantial decline in Gardasil sales to achieve 5% top-line growth. Eager to ease investor anxieties surrounding Keytruda's impending loss of exclusivity, leadership aggressively highlighted recent acquisitions and advanced clinical assets. By raising its mid-2030s commercial opportunity estimate to $70 billion, management aims to underscore a path to sustainable, diversified growth well beyond its core cancer franchise.
Keytruda Anchors Revenue While Vaccines Drag
Merck generated $16.4 billion in fourth-quarter sales, representing a 5% year-over-year increase that leaned heavily on its dominant oncology portfolio. The Keytruda product family drove $8.4 billion of this total, securing 5% growth despite a $200 million domestic headwind related to purchasing timing. Conversely, the company's vaccine segment faced severe pressure, with Gardasil sales plummeting 35% to $1.0 billion due to abruptly lower demand in both China and Japan. On the bottom line, non-GAAP earnings per share came in at $2.04, with gross margins contracting 1.1 percentage points to 79.7% primarily from higher inventory reserves.
Acquisition Charges Obscure Modest 2026 Growth Guidance
For the full year 2026, Merck projects total revenue between $65.5 billion and $67.0 billion, translating to a muted underlying growth rate of 1% to 3%. CFO Caroline Litchfield guided for non-GAAP earnings per share between $5.00 and $5.15, though this figure significantly incorporates a $9 billion one-time charge associated with the recent acquisition of Sidera Therapeutics. Excluding these transaction costs and ongoing operational financing, the midpoint of the earnings forecast would jump to $9.03 per share. This baseline projection absorbs approximately $2.5 billion in expected regional generic competition and localized pricing headwinds, primarily affecting older cardio-metabolic therapies.
Broadening Beyond Keytruda With Strategic Acquisitions
Management relentlessly focused the call on pipeline expansion, explicitly combatting concerns over Keytruda's forecasted 2028 patent expiration. Recent business development fueled immediate commercial contributions, with the newly acquired Verona Pharma asset, O2Ver, contributing $178 million for chronic obstructive pulmonary disease maintenance treatment. Looking further ahead, the Sidera Therapeutics integration brought MK1406, a phase three preventative influenza antiviral that CEO Robert Davis heralded as possessing greater than $5 billion in peak revenue potential. Bolstered by these additions, Davis asserted the company now possesses line of sight to over $70 billion in cumulative commercial opportunity by the mid-2030s.
Defending Core Assets Amidst Intensifying Competition
During the question and answer segment, analysts pressed leadership on both the defensive and offensive positioning of their critical franchises. When questioned regarding the exact intellectual property timeline for Keytruda, Davis revealed increased confidence in defending supplementary manufacturing patents until late 2029, even as the company conservatively models for a 2028 expiration. Regarding cardiovascular expansion, President of Research Labs Dean Li outlined an ambitious agenda for enlicitide, the company's investigational oral PCSK9 inhibitor, emphasizing ongoing dialogue with regulatory bodies to define precise surrogate endpoints for upcoming orphan disease trials.